Near-term business remains in choppy waters
31/01/25 -"Despite a >10% reduction in our target price, as detailed in the EPS section, we continue to see significant upside potential for Carl Zeiss Meditec. This is supported by the company's strong ..."
Pages
65
Language
English
Published on
31/01/25
You may also be interested by these reports :
12/09/25
DiaSorin appears to be making significant progress in the testing space. The launch of speciality tests, introduction of the Plex platform, and ...
05/09/25
Bastide reported FY24/25 revenue in line with guidance and our forecast. The more technical business activities remain the primary driver of organic ...
05/09/25
Since we last pushed Philips’ (Buy; Netherlands) investment case in January 2024, its share price performance has been glaringly ahead of the MedTech ...
04/09/25
bioMerieux’s H1 profitability surpassed expectations. Topline growth was driven by robust performance across both segments. However, weakness in ...